Hookipa Pharma (HOOK) AI Stock Analysis

• Market Cap: $11.53M
• Dividend Yield: N/A
• Average Volume (3M): 15.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: -71.52%
• EPS Growth: 1.45%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,930,789
• 10 Day Avg. Volume: 21,467
• 30 Day Avg. Volume: 15,706
• PEG Ratio: <0.01
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 0.57
• P/FCF Ratio: -0.33
• Enterprise Value/Market Cap: -1.55
• Enterprise Value/Revenue: -1.20
• Enterprise Value/Gross Profit: -1.20
• Enterprise Value/Ebitda: 0.33
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $1.00 ▲(12.36% Upside)

Hookipa Pharma's overall stock score is low due to severe financial difficulties, negative technical indicators, and poor valuation metrics. The company's strategic decisions to sell assets and liquidate further exacerbate the risk, making it a highly speculative investment.

Positive Factors

Strategic Partnerships

Strategic partnerships provide a recurring revenue stream through upfront and milestone payments, supporting financial stability and growth.

Innovative Immunotherapy Focus

Focus on innovative immunotherapies positions the company in high-growth markets, leveraging proprietary technology for competitive advantage.

Low Leverage Risk

Minimal debt levels reduce financial risk, providing flexibility in financial management and resilience against economic downturns.

Negative Factors

Asset Sale and Liquidation

Asset sale and liquidation plans indicate a winding down of operations, posing a significant risk to the company's future viability and investor returns.

Zero Revenue in 2024

Lack of revenue generation and negative margins highlight severe financial challenges, threatening long-term sustainability and necessitating strategic shifts.

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiency and the need for external capital, impacting the company's ability to sustain operations.

Hookipa Pharma Business Overview & Revenue Model

Company Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

How the Company Makes Money

Hookipa Pharma generates revenue primarily through strategic partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on development progress, and royalties on future sales of products developed in collaboration. Additionally, the company may receive funding through grants or government support aimed at advancing its clinical trials. As Hookipa progresses through clinical stages and achieves regulatory milestones, it can unlock significant financial resources from its partners, contributing to its overall revenue stream.

Hookipa Pharma Financial Statement Overview

Summary

Hookipa Pharma's financial performance is severely challenged, with zero revenue in 2024 and substantial negative margins across the board. The balance sheet shows low leverage risk but declining equity and ongoing losses. Cash flow is negative, indicating significant operational and financial risks.

Income Statement

Hookipa Pharma's income statement reveals a challenging financial performance with zero revenue in 2024, a significant decline from previous years. The gross profit margin is non-existent, and they have substantial negative EBIT and EBITDA margins. The net profit margin is also negative, reflecting ongoing losses. Revenue growth has been inconsistent, with a notable drop in the most recent year. The company's trajectory indicates financial instability and a need for strategic adjustments to improve revenue streams.

Balance Sheet

The balance sheet of Hookipa Pharma shows a moderate level of financial stability. The debt-to-equity ratio is low due to minimal debt, indicating low leverage risk. However, the return on equity is negative, driven by consecutive net losses. The equity ratio is satisfactory, suggesting a capital structure with a higher proportion of equity funding. Despite the low debt levels, the declining equity value and recurring losses raise concerns about long-term solvency and the need for improved operational performance.

Cash Flow

Cash flow analysis highlights significant challenges, with negative operating and free cash flows in 2024, further deteriorating from the previous year. The free cash flow to net income ratio and operating cash flow to net income ratio are adverse, reflecting cash outflows exceeding earnings. The free cash flow growth rate is negative, indicating a need for better cash management and operational efficiency. Overall, cash flow constraints pose a risk to sustaining operations without fresh capital infusions.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.86M	43.95M	20.13M	14.25M	18.45M	19.58M
Gross Profit	14.86M	41.19M	16.58M	10.65M	13.81M	-33.55M
EBITDA	-53.86M	-40.85M	-77.34M	-60.40M	-70.13M	-39.15M
Net Income	-56.00M	-43.50M	-81.58M	-64.92M	-75.67M	-44.08M
Balance Sheet
Total Assets	52.71M	82.55M	161.34M	170.45M	126.05M	187.82M
Cash, Cash Equivalents and Short-Term Investments	34.23M	39.68M	117.10M	113.44M	65.92M	143.18M
Total Debt	546.00K	875.00K	6.56M	6.50M	10.63M	10.77M
Total Liabilities	24.02M	31.33M	71.48M	67.94M	36.45M	31.69M
Stockholders Equity	28.68M	51.21M	89.86M	102.52M	89.59M	156.12M
Cash Flow
Free Cash Flow	-45.58M	-77.17M	-61.68M	-25.01M	-78.60M	-41.71M
Operating Cash Flow	-45.53M	-76.98M	-57.52M	-20.00M	-66.02M	-39.34M
Investing Cash Flow	-53.00K	-194.00K	-4.16M	-5.02M	-12.58M	-2.37M
Financing Cash Flow	-443.00K	-1.28M	65.67M	72.27M	-235.00K	73.42M

Hookipa Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOOK, the sentiment is Positive. The current price of 0.89 is below the 20-day moving average (MA) of 0.90, above the 50-day MA of 0.89, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 66.10 is Neutral, neither overbought nor oversold. The STOCH value of 93.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOOK.

Hookipa Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHIO	46 Neutral	$12.27M	-0.51	-107.58%	―	―	83.95%
PHGE	44 Neutral	$4.09M	-0.09	-154.50%	―	―	54.25%
KZIA	41 Neutral	$81.17M	-0.58	―	―	-98.25%	63.05%
HOOK	40 Underperform	$11.53M	-0.21	-97.61%	―	-71.52%	1.45%
WINT	39 Underperform	$677.55K	>-0.01	―	―	―	99.09%